CAR-T and CAR-Treg Therapies for Autoimmunity: Innovations and Challenges Review

Michael D. Lovelace authored a 32.9 KB review document on figshare, last updated April 30, 2026. The text examines the application of CAR-T, CAR-Treg, and HSC therapies for treating autoimmune diseases like Multiple Sclerosis and Type 1 Diabetes. It discusses biological principles, clinical trials, and challenges such as manufacturing costs and off-target effects.

Use Cases

• Literature review on CAR-T and CAR-Treg mechanisms for autoimmunity based on the described biological principles
• Analysis of clinical trial progress for autoimmune therapies based on the mention of ongoing trials
• Assessment of manufacturing and cost challenges in cell therapy based on the described production processes

Strengths

• Document is under a permissive CC-BY-4.0 license, allowing broad reuse.
• Specific file size of 32.9 KB indicates a concise, focused text document.
• Explicitly discusses named therapies (CAR-T, CAR-Treg, HSC) and diseases (MS, T1D).

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The 32.9 KB size suggests a very limited scope, likely a single review document.

Provenance

Source

Michael D. Lovelace via figshare

Collection Method

Authored review document.

Freshness

Last updated 2026-04-30 05:40:32; freshness should be verified.